Literature DB >> 1692971

Morphological transformation of human keratinocytes expressing the LMP gene of Epstein-Barr virus.

R Fåhraeus1, L Rymo, J S Rhim, G Klein.   

Abstract

The association of Epstein-Barr virus (EBV) with nasopharyngeal carcinoma (NPC) has been known for some time, but the precise role of EBV in this cancer is poorly understood, due partly to the lack of an in vitro system for studying NPC cells and the effect of EBV on epithelial cells. Biopsies of NPC tumours have revealed expression of the EBV latent membrane protein (LMP) in 65% of cases, suggesting that in at least some NPC tumours LMP may contribute to cell transformation. Here we address the question of the effect of LMP expression on epithelial cells. Transfection of an immortalized, non-tumorigenic keratinocyte cell line (RHEK-1) with the LMP gene causes a striking morphological transformation: the originally flat, polygonal colonies change to bundles of spindle-shaped cells that form multilayer foci, and cytokeratin expression is down-regulated. Our results suggest that LMP expression may be an important causal factor in the development of NPC.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1692971     DOI: 10.1038/345447a0

Source DB:  PubMed          Journal:  Nature        ISSN: 0028-0836            Impact factor:   49.962


  65 in total

1.  Analysis of the Epstein-Barr virus (EBV) latent membrane protein 1 (LMP-1) gene and promoter in Hodgkin's disease isolates: selection against EBV variants with mutations in the LMP-1 promoter ATF-1/CREB-1 binding site.

Authors:  K Sandvej; B S Andresen; X G Zhou; N Gregersen; S Hamilton-Dutoit
Journal:  Mol Pathol       Date:  2000-10

2.  The Epstein-Barr virus oncogene product, latent membrane protein 1, induces the downregulation of E-cadherin gene expression via activation of DNA methyltransferases.

Authors:  Chi-Neu Tsai; Chia-Lung Tsai; Ka-Po Tse; Hwan-You Chang; Yu-Sun Chang
Journal:  Proc Natl Acad Sci U S A       Date:  2002-07-10       Impact factor: 11.205

3.  Expression of Epstein-Barr virus genes and of lymphocyte activation molecules in undifferentiated nasopharyngeal carcinomas.

Authors:  G Niedobitek; L S Young; C K Sam; L Brooks; U Prasad; A B Rickinson
Journal:  Am J Pathol       Date:  1992-04       Impact factor: 4.307

4.  Phenotypes of Epstein-Barr virus LMP1 deletion mutants indicate transmembrane and amino-terminal cytoplasmic domains necessary for effects in B-lymphoma cells.

Authors:  D Liebowitz; J Mannick; K Takada; E Kieff
Journal:  J Virol       Date:  1992-07       Impact factor: 5.103

5.  Oncogenic activity of Epstein-Barr virus latent membrane protein 1 (LMP-1) is down-regulated by lytic LMP-1.

Authors:  Jyotsna Pandya; Dennis M Walling
Journal:  J Virol       Date:  2006-08       Impact factor: 5.103

6.  Epstein-Barr virus latent membrane protein expression in Hodgkin and Reed-Sternberg cells.

Authors:  H Herbst; F Dallenbach; M Hummel; G Niedobitek; S Pileri; N Müller-Lantzsch; H Stein
Journal:  Proc Natl Acad Sci U S A       Date:  1991-06-01       Impact factor: 11.205

7.  Immunohistochemical demonstration of different latent membrane protein-1 epitopes of Epstein-Barr virus in lymphoproliferative diseases.

Authors:  N M Jiwa; J J Oudejans; D F Dukers; W Vos; A Horstman; P van der Valk; J M Middledorp; J M Walboomers; C J Meijer
Journal:  J Clin Pathol       Date:  1995-05       Impact factor: 3.411

8.  Immortalization of human primary B lymphocytes in vitro with DNA.

Authors:  B Kempkes; D Pich; R Zeidler; W Hammerschmidt
Journal:  Proc Natl Acad Sci U S A       Date:  1995-06-20       Impact factor: 11.205

9.  Augmented latent membrane protein 1 expression from Epstein-Barr virus episomes with minimal terminal repeats.

Authors:  Allison M Repic; Mingxia Shi; Rona S Scott; John W Sixbey
Journal:  J Virol       Date:  2009-12-16       Impact factor: 5.103

10.  Variable expression of latent membrane protein in nasopharyngeal carcinoma can be related to methylation status of the Epstein-Barr virus BNLF-1 5'-flanking region.

Authors:  L F Hu; J Minarovits; S L Cao; B Contreras-Salazar; L Rymo; K Falk; G Klein; I Ernberg
Journal:  J Virol       Date:  1991-03       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.